Analysts’ Recent Ratings Updates for Liquidia (LQDA)

A number of firms have modified their ratings and price targets on shares of Liquidia (NASDAQ: LQDA) recently:

• 8/13/2026 – Liquidia had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $106.00 price target on the stock.
• 8/13/2026 – Liquidia had its price target raised by Wells Fargo & Company from $62.00 to $108.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Liquidia was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/13/2026 – Liquidia had its price target raised by Bank of America Corporation from $79.00 to $92.00. They now have a “neutral” rating on the stock.
• 8/12/2026 – Liquidia had its price target raised by BTIG Research from $109.00 to $111.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Liquidia had its price target raised by Needham & Company LLC from $70.00 to $110.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Liquidia was downgraded by Lifesci Capital from “outperform” to “hold”. They now have a $90.00 price target on the stock.
• 7/24/2026 – Liquidia was given a new $130.00 price target by Royal Bank Of Canada.
• 7/24/2026 – Liquidia was given a new $36.00 price target by HC Wainwright.
• 7/24/2026 – Liquidia was given a new $129.00 price target by Piper Sandler.
• 7/24/2026 – Liquidia was given a new $130.00 price target by Stephens.
• 7/23/2026 – Liquidia had its price target raised by HC Wainwright from $75.00 to $130.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Liquidia had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other news, Director Paul B. Manning sold 200,000 shares of Liquidia stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the transaction, the director owned 716,311 shares in the company, valued at approximately $45,779,436.01. This trade represents a 21.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total value of $17,063,005.67. Following the completion of the sale, the director owned 1,176,184 shares of the company’s stock, valued at $82,838,639.12. This trade represents a 17.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,824,010 shares of company stock worth $129,702,737 over the last quarter. 25.60% of the stock is currently owned by insiders.

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).